Fatimasol Injection

Adult administration

Typically, an adult requires a dose of 500–1,000mL administered by slow intravenous infusion. The administration rate is 300–500mL per hour (75–120 drops per minute).

Child administration

For children, the administration rate is 50–100mL per hour.

This medication contains glucose, which may increase the consumption of vitamin B1 (thiamine) in the body when administered intravenously, leading to severe deficiency, so caution is advised. Allergic reactions or hypersensitivity reactions such as anaphylaxis may occur during the administration of this medication. If symptoms occur, administration should be stopped immediately, and appropriate treatment should be initiated. As this solution contains potassium, it should be avoided in patients at risk of hyperkalemia, especially those with impaired renal function or heart disease, or blood potassium levels should be monitored regularly. In diabetic patients or those with difficulty controlling blood sugar, glucose infusion can cause a rapid increase in blood sugar, so blood sugar levels should be monitored frequently, and insulin therapy should be combined if necessary. Due to the sodium and chloride content, electrolyte imbalances such as hypernatremia, hyperchloremia, and metabolic acidosis may occur, so patients with heart or liver disease should be monitored closely. This medication may cause hyponatremia, so especially in children, the elderly, post-surgical patients, and those taking certain medications, blood sodium levels should be monitored periodically. Excessive fluid administration may exacerbate the risk of pulmonary edema or congestive heart failure, so fluid status and electrolyte balance should be monitored carefully. In cases of severe malnutrition when nutritional support is resumed, refeeding syndrome may occur; therefore, potassium, phosphorus, magnesium levels, and thiamine status should be monitored and nutrition should be increased slowly. This medication should be avoided in patients with lactic acidosis, hyperkalemia, hyperhydration, and hyperglycemia, and those with a history of hypersensitivity should not use it. In patients with severely impaired renal function, heart failure, hepatic impairment, or urinary obstruction, greater care should be taken when using this medication, and electrolyte and fluid status should be closely monitored. Rapid or large volume administration of this medication may lead to serious side effects such as cerebral edema, pulmonary edema, and hyperkalemia, so the rate and dosage of administration should be strictly controlled. Regularly monitor blood sugar, electrolyte levels, and fluid balance to detect abnormalities early and respond appropriately. Be cautious of drug interactions, particularly when used with medications that can cause hyperkalemia, lithium, or blood sugar control medications, monitoring their blood concentrations closely. During pregnancy, this medication should only be administered when the therapeutic benefits outweigh the risks to the fetus, and maternal and newborn blood glucose levels should be monitored carefully during delivery. In neonates or low-birth-weight infants, there is a high risk of blood glucose abnormalities and electrolyte imbalances, so careful monitoring is required. Older adults may require dosage adjustment and caution due to decreased bodily function. When administered, a daily dosage of 500mL or more than 20mL per hour is recommended, and care should be taken to prevent air embolism when connecting containers. This medication should be stored in a sealed container to avoid exposure to air and is best kept at room temperature between 1 to 30 degrees Celsius. If stored in a glass container, it can be used safely for 36 months from the manufacturing date, and if stored in an infusion plastic container, it can be used safely for 18 months.

Serious side effects

• Anaphylaxis
• systemic urticaria and erythema
• cardiac arrest
• cerebral edema
• pulmonary edema
• peripheral edema
• difficulty breathing
• urticaria
• severe swelling (edema)
• diaphoresis

Mild side effects

• Rash, itching, vomiting, hypertension, tachycardia, chills, blistering at the injection site, extravasation, venous thrombosis, phlebitis, pain at the injection site.
• Hyperosmolar hyperglycemia status, fluid overload, refeeding syndrome, hyponatremia encephalopathy, hypernatremia and hyperchloremia, hyperkalemia, hyperglycemia.

This medication should be stored in a sealed container to prevent exposure to air, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. If contained in a glass container, it can be used for 36 months from the manufacturing date, and if contained in an infusion plastic container, it can be used safely for 18 months.

Appearance

A colorless and transparent liquid with a slight salty and sweet taste filled in a colorless and transparent glass or plastic infusion container.

Package unit

200mL/bag, 500mL/bag